English

Aralez Pharmaceuticals Inc.

EDGAR

Quarterly report (10-Q) · filed 2018-05-08

18 filing records in this dataset, filed from 2015-12-14 to 2018-05-08. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

38.1 million Unit1

2018 Q1 · Unit1

Exact inputs and evidence

Revenue: 38081000 Unit1 Source

Operating margin

-36.94%

2018 Q1 · %

Exact inputs and evidence

Operating Income: -14069000 Unit1 Source
Revenue: 38081000 Unit1 Source

Operating cash flow

18.6 million Unit1

2018 Q1 · Unit1

Exact inputs and evidence

Operating Cash Flow: 18577000 Unit1 Source

Free cash flow

18.5 million Unit1

2018 Q1 · Unit1

Exact inputs and evidence

Operating Cash Flow: 18577000 Unit1 Source
Capital Expenditure: 32000 Unit1 Source

Cash and cash equivalents: 43.9 million Unit1 2018-03-31 Source
Exact value

43887000 Unit1
Long-term debt including current maturities: 74.5 million Unit1 2016-06-30 Source
Exact value

74498000 Unit1
Shares outstanding: 67.2 million Unit16 2018-03-31 Source
Exact value

67194277 Unit16

Reported share-count change

2.05% · 1.35 million Unit16

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

65845754 Unit16 · 2017-03-31· Source
67194277 Unit16 · 2018-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

118 million Unit1

2017-04-01 – 2018-03-31

Exact inputs and evidence

Revenue: 27618000 Unit1 · 2017-04-01 – 2017-06-30 Source
Revenue: 24338000 Unit1 · 2017-07-01 – 2017-09-30 Source
Revenue: 28022000 Unit1 · 2017-10-01 – 2017-12-31 Source
Revenue: 38081000 Unit1 · 2018-01-01 – 2018-03-31 Source

Net income

-117 million Unit1

2017-04-01 – 2018-03-31

Exact inputs and evidence

Net income: -27520000 Unit1 · 2017-04-01 – 2017-06-30 Source
Net income: -24441000 Unit1 · 2017-07-01 – 2017-09-30 Source
Net income: -45767000 Unit1 · 2017-10-01 – 2017-12-31 Source
Net income: -19741000 Unit1 · 2018-01-01 – 2018-03-31 Source

Operating cash flow

-20.7 million Unit1

2017-04-01 – 2018-03-31

Exact inputs and evidence

Operating cash flow: -4112000 Unit1 · 2017-01-01 – 2017-06-30 Source
Operating cash flow: 10488000 Unit1 · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -19191000 Unit1 · 2017-01-01 – 2017-09-30 Source
Operating cash flow: -4112000 Unit1 · 2017-01-01 – 2017-06-30 Source
Operating cash flow: -28800000 Unit1 · 2017-01-01 – 2017-12-31 Source
Operating cash flow: -19191000 Unit1 · 2017-01-01 – 2017-09-30 Source
Operating cash flow: 18577000 Unit1 · 2018-01-01 – 2018-03-31 Source

Capital expenditure

393 thousand Unit1

2017-04-01 – 2018-03-31

Exact inputs and evidence

Capital expenditure: 1702000 Unit1 · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 1461000 Unit1 · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 1702000 Unit1 · 2017-01-01 – 2017-09-30 Source
Capital expenditure: 1702000 Unit1 · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 1822000 Unit1 · 2017-01-01 – 2017-12-31 Source
Capital expenditure: 1702000 Unit1 · 2017-01-01 – 2017-09-30 Source
Capital expenditure: 32000 Unit1 · 2018-01-01 – 2018-03-31 Source

Free cash flow

-21.1 million Unit1

2017-04-01 – 2018-03-31

Exact inputs and evidence

Operating cash flow: -4112000 Unit1 · 2017-01-01 – 2017-06-30 Source
Operating cash flow: 10488000 Unit1 · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -19191000 Unit1 · 2017-01-01 – 2017-09-30 Source
Operating cash flow: -4112000 Unit1 · 2017-01-01 – 2017-06-30 Source
Operating cash flow: -28800000 Unit1 · 2017-01-01 – 2017-12-31 Source
Operating cash flow: -19191000 Unit1 · 2017-01-01 – 2017-09-30 Source
Operating cash flow: 18577000 Unit1 · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 1702000 Unit1 · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 1461000 Unit1 · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 1702000 Unit1 · 2017-01-01 – 2017-09-30 Source
Capital expenditure: 1702000 Unit1 · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 1822000 Unit1 · 2017-01-01 – 2017-12-31 Source
Capital expenditure: 1702000 Unit1 · 2017-01-01 – 2017-09-30 Source
Capital expenditure: 32000 Unit1 · 2018-01-01 – 2018-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2018-05-08.

Financial data available through: 2017-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2017-12-31
Operating income: 4 of 11 periods available· newest 2017-12-31
Net income: 3 of 11 periods available· newest 2017-12-31
Operating cash flow: 4 of 11 periods available· newest 2017-12-31
Capital expenditure: 4 of 11 periods available· newest 2017-12-31
Total assets: 3 of 11 periods available· newest 2017-12-31
Total liabilities: 3 of 11 periods available· newest 2017-12-31
Current assets: 3 of 11 periods available· newest 2017-12-31
Current liabilities: 3 of 11 periods available· newest 2017-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2017-12-31
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2017-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+95.2%

Prior period

Unit1 54.27 million

2016-01-01 – 2016-12-31
Current period

Unit1 105.95 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

105947000 − 54270000 = 51677000 Unit1

54270000 Unit1 · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
105947000 Unit1 · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Aralez Pharmaceuticals Inc. · 2017-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Year-over-year change in Revenue: 51677000 Unit1 Concept: fundies:Revenue Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 105947000 Unit1 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#2120298 Filing: 000155837018002031 Input fundies:Revenue: 54270000 Unit1 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#2119251 Filing: 000155837018002031
The citation records this snapshot. The page link may show a newer release later.
Net income
−Unit1 22.22 million

Prior period

−Unit1 102.98 million

2016-01-01 – 2016-12-31
Current period

−Unit1 125.2 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-125200000 − -102978000 = -22222000 Unit1

-102978000 Unit1 · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-125200000 Unit1 · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Aralez Pharmaceuticals Inc. · 2017-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Year-over-year change in Net income: -22222000 Unit1 Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -125200000 Unit1 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018004351/arlz-20180331.xml#910880 Filing: 000155837018004351 Input fundies:NetIncome: -102978000 Unit1 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1731741 Filing: 000155837018002031
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit1 54.93 million

Prior period

−Unit1 83.73 million

2016-01-01 – 2016-12-31
Current period

−Unit1 28.8 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

-28800000 − -83731000 = 54931000 Unit1

-83731000 Unit1 · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
-28800000 Unit1 · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Aralez Pharmaceuticals Inc. · 2017-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Year-over-year change in Operating cash flow: 54931000 Unit1 Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -28800000 Unit1 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018004351/arlz-20180331.xml#910365 Filing: 000155837018004351 Input fundies:OperatingCashFlow: -83731000 Unit1 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1730634 Filing: 000155837018002031
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-56.3%

Prior period

Unit1 4.17 million

2016-01-01 – 2016-12-31
Current period

Unit1 1.82 million

2017-01-01 – 2017-12-31

Exact inputs and evidence

1822000 − 4166000 = -2344000 Unit1

4166000 Unit1 · 2016-01-01 – 2016-12-31
Inspect prior input Prior source
1822000 Unit1 · 2017-01-01 – 2017-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Aralez Pharmaceuticals Inc. · 2017-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Year-over-year change in Capital expenditure: -2344000 Unit1 Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1822000 Unit1 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1852629 Filing: 000155837018002031 Input fundies:CapitalExpenditure: 4166000 Unit1 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1852439 Filing: 000155837018002031
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue Unit1 105.95 million 100% of revenue
Operating costs Derived Unit1 202.45 million 191% of revenue
Operating income −Unit1 96.5 million −91% of revenue
Tax, interest and other Derived Unit1 28.7 million 27% of revenue
Net income −Unit1 125.2 million −118% of revenue

Cash

Operating cash flow −Unit1 28.8 million −27% of revenue
Capital expenditure Unit1 1.82 million 1.7% of revenue
Free cash flow Derived −Unit1 30.62 million −29% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 Not shown: operating income or net income is not reported.
2015 Operating loss: operating costs were 275% of revenue.
2016 Operating loss: operating costs were 289% of revenue.
2017 Operating loss: operating costs were 191% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	32394000	15818000 Derived	16576000	Unavailable	Unavailable	359000 Derived	Source 2014-01-01 – 2014-12-31: 32394000 Unit1 Inspect Revenue Open source 2014-01-01 – 2014-12-31: 16576000 Unit1 Inspect Operating Income Open source 2014-01-01 – 2014-12-31: 366000 Unit1 Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 7000 Unit1 Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	21391000	58857000 Derived	-37466000	317000 Derived	-37783000	-17029000 Derived	Source 2015-01-01 – 2015-12-31: 21391000 Unit1 Inspect Revenue Open source 2015-01-01 – 2015-12-31: -37466000 Unit1 Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -37783000 Unit1 Inspect Net Income Open source 2015-01-01 – 2015-12-31: -16789000 Unit1 Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 240000 Unit1 Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	54270000	156854000 Derived	-102584000	394000 Derived	-102978000	-87897000 Derived	Source 2016-01-01 – 2016-12-31: 54270000 Unit1 Inspect Revenue Open source 2016-01-01 – 2016-12-31: -102584000 Unit1 Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -102978000 Unit1 Inspect Net Income Open source 2016-01-01 – 2016-12-31: -83731000 Unit1 Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 4166000 Unit1 Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	105947000	202450000 Derived	-96503000	28697000 Derived	-125200000	-30622000 Derived	Source 2017-01-01 – 2017-12-31: 105947000 Unit1 Inspect Revenue Open source 2017-01-01 – 2017-12-31: -96503000 Unit1 Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -125200000 Unit1 Inspect Net Income Open source 2017-01-01 – 2017-12-31: -28800000 Unit1 Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1822000 Unit1 Inspect Capital Expenditure Open source

Amounts are exact, in Unit1.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit1 105.9M 2017

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit1)	Source evidence
20142014-12-31	Revenue	32394000	Revenue: 32394000 Open source
20152015-12-31	Revenue	21391000	Revenue: 21391000 Open source
20162016-12-31	Revenue	54270000	Revenue: 54270000 Open source
20172017-12-31	Revenue	105947000	Revenue: 105947000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

95.2% 2017

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	No prior comparable period	Revenue: 32394000 Open source
20152015-12-31	Year over year	-34%	Revenue: 21391000 Open source Revenue: 32394000 Open source
20162016-12-31	Year over year	153.7%	Revenue: 54270000 Open source Revenue: 21391000 Open source
20172017-12-31	Year over year	95.2%	Revenue: 105947000 Open source Revenue: 54270000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -91.1% 2017

Net margin -118.2% 2017

Free cash flow margin -28.9% 2017

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Operating margin	51.2%	Operating Income: 16576000 Open source Revenue: 32394000 Open source
20152015-12-31	Operating margin	-175.1%	Operating Income: -37466000 Open source Revenue: 21391000 Open source
20162016-12-31	Operating margin	-189%	Operating Income: -102584000 Open source Revenue: 54270000 Open source
20172017-12-31	Operating margin	-91.1%	Operating Income: -96503000 Open source Revenue: 105947000 Open source
2014-12-31	Net margin	Not reported	Revenue: 32394000 Open source
20152015-12-31	Net margin	-176.6%	Net Income: -37783000 Open source Revenue: 21391000 Open source
20162016-12-31	Net margin	-189.8%	Net Income: -102978000 Open source Revenue: 54270000 Open source
20172017-12-31	Net margin	-118.2%	Net Income: -125200000 Open source Revenue: 105947000 Open source
20142014-12-31	Free cash flow margin	1.1%	Revenue: 32394000 Open source Operating Cash Flow: 366000 Open source Capital Expenditure: 7000 Open source
20152015-12-31	Free cash flow margin	-79.6%	Revenue: 21391000 Open source Operating Cash Flow: -16789000 Open source Capital Expenditure: 240000 Open source
20162016-12-31	Free cash flow margin	-162%	Revenue: 54270000 Open source Operating Cash Flow: -83731000 Open source Capital Expenditure: 4166000 Open source
20172017-12-31	Free cash flow margin	-28.9%	Revenue: 105947000 Open source Operating Cash Flow: -28800000 Open source Capital Expenditure: 1822000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit1 -28.8M 2017

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit1)	Source evidence
20142014-12-31	Operating cash flow	366000	Operating Cash Flow: 366000 Open source
20152015-12-31	Operating cash flow	-16789000	Operating Cash Flow: -16789000 Open source
20162016-12-31	Operating cash flow	-83731000	Operating Cash Flow: -83731000 Open source
20172017-12-31	Operating cash flow	-28800000	Operating Cash Flow: -28800000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit1 -30.6M 2017

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit1)	Source evidence
20142014-12-31	Free cash flow	359000	Operating Cash Flow: 366000 Open source Capital Expenditure: 7000 Open source
20152015-12-31	Free cash flow	-17029000	Operating Cash Flow: -16789000 Open source Capital Expenditure: 240000 Open source
20162016-12-31	Free cash flow	-87897000	Operating Cash Flow: -83731000 Open source Capital Expenditure: 4166000 Open source
20172017-12-31	Free cash flow	-30622000	Operating Cash Flow: -28800000 Open source Capital Expenditure: 1822000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

96.6% 2017

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2014-12-31	Liabilities / assets	Not reported	No source recorded
20152015-12-31	Liabilities / assets	54.2%	Total Liabilities: 17475000 Open source Total Assets: 32258000 Open source
20162016-12-31	Liabilities / assets	76.9%	Total Liabilities: 397891000 Open source Total Assets: 517377000 Open source
20172017-12-31	Liabilities / assets	96.6%	Total Liabilities: 438258000 Open source Total Assets: 453477000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.78× 2017

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2014-12-31	Current assets / current liabilities	Not reported	No source recorded
20152015-12-31	Current assets / current liabilities	1.94×	Current Assets: 32007000 Open source Current Liabilities: 16489000 Open source
20162016-12-31	Current assets / current liabilities	1.61×	Current Assets: 92331000 Open source Current Liabilities: 57274000 Open source
20172017-12-31	Current assets / current liabilities	0.78×	Current Assets: 52675000 Open source Current Liabilities: 67860000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	Unavailable Not reported for this period.	Unit1 366,000 Exact value Exact value: 366000 Unit1 2014-01-01 – 2014-12-31: 366000 Unit1 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aralez Pharmaceuticals Inc. · 2014-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Operating Cash Flow: 366000 Unit1 Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=Unit1&dimensions= Input fundies:OperatingCashFlow: 366000 Unit1 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837017001659/arlz-20161231.xml#1690932 Filing: 000155837017001659 The citation records this snapshot. The page link may show a newer release later.	Unit1 7,000 Exact value Exact value: 7000 Unit1 2014-01-01 – 2014-12-31: 7000 Unit1 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aralez Pharmaceuticals Inc. · 2014-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Capital Expenditure: 7000 Unit1 Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=Unit1&dimensions= Input fundies:CapitalExpenditure: 7000 Unit1 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837017001659/arlz-20161231.xml#1779579 Filing: 000155837017001659 The citation records this snapshot. The page link may show a newer release later.	Unit1 359,000 Calculation and evidence 366000 − 7000 Unit1 Exact free cash flow: 359000 Unit1 2014-01-01 – 2014-12-31: 366000 Unit1 · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 7000 Unit1 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aralez Pharmaceuticals Inc. · 2014-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Free cash flow: 359000 Unit1 Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 366000 Unit1 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837017001659/arlz-20161231.xml#1690932 Filing: 000155837017001659 Input fundies:CapitalExpenditure: 7000 Unit1 (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837017001659/arlz-20161231.xml#1779579 Filing: 000155837017001659 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−Unit1 37.78 million Exact value Exact value: -37783000 Unit1 2015-01-01 – 2015-12-31: -37783000 Unit1 Inspect Net Income Open source Share or cite Citation for Net Income · Aralez Pharmaceuticals Inc. · 2015-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Net Income: -37783000 Unit1 Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit1&dimensions= Input fundies:NetIncome: -37783000 Unit1 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1731018 Filing: 000155837018002031 The citation records this snapshot. The page link may show a newer release later.	−Unit1 16.79 million Exact value Exact value: -16789000 Unit1 2015-01-01 – 2015-12-31: -16789000 Unit1 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aralez Pharmaceuticals Inc. · 2015-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Operating Cash Flow: -16789000 Unit1 Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit1&dimensions= Input fundies:OperatingCashFlow: -16789000 Unit1 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1730442 Filing: 000155837018002031 The citation records this snapshot. The page link may show a newer release later.	Unit1 240,000 Exact value Exact value: 240000 Unit1 2015-01-01 – 2015-12-31: 240000 Unit1 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aralez Pharmaceuticals Inc. · 2015-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Capital Expenditure: 240000 Unit1 Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=Unit1&dimensions= Input fundies:CapitalExpenditure: 240000 Unit1 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1852250 Filing: 000155837018002031 The citation records this snapshot. The page link may show a newer release later.	−Unit1 17.03 million Calculation and evidence -16789000 − 240000 Unit1 Exact free cash flow: -17029000 Unit1 2015-01-01 – 2015-12-31: -16789000 Unit1 · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 240000 Unit1 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aralez Pharmaceuticals Inc. · 2015-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Free cash flow: -17029000 Unit1 Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16789000 Unit1 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1730442 Filing: 000155837018002031 Input fundies:CapitalExpenditure: 240000 Unit1 (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1852250 Filing: 000155837018002031 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−Unit1 102.98 million Exact value Exact value: -102978000 Unit1 2016-01-01 – 2016-12-31: -102978000 Unit1 Inspect Net Income Open source Share or cite Citation for Net Income · Aralez Pharmaceuticals Inc. · 2016-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Net Income: -102978000 Unit1 Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit1&dimensions= Input fundies:NetIncome: -102978000 Unit1 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1731741 Filing: 000155837018002031 The citation records this snapshot. The page link may show a newer release later.	−Unit1 83.73 million Exact value Exact value: -83731000 Unit1 2016-01-01 – 2016-12-31: -83731000 Unit1 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aralez Pharmaceuticals Inc. · 2016-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Operating Cash Flow: -83731000 Unit1 Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit1&dimensions= Input fundies:OperatingCashFlow: -83731000 Unit1 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1730634 Filing: 000155837018002031 The citation records this snapshot. The page link may show a newer release later.	Unit1 4.17 million Exact value Exact value: 4166000 Unit1 2016-01-01 – 2016-12-31: 4166000 Unit1 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aralez Pharmaceuticals Inc. · 2016-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Capital Expenditure: 4166000 Unit1 Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=Unit1&dimensions= Input fundies:CapitalExpenditure: 4166000 Unit1 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1852439 Filing: 000155837018002031 The citation records this snapshot. The page link may show a newer release later.	−Unit1 87.9 million Calculation and evidence -83731000 − 4166000 Unit1 Exact free cash flow: -87897000 Unit1 2016-01-01 – 2016-12-31: -83731000 Unit1 · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 4166000 Unit1 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aralez Pharmaceuticals Inc. · 2016-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Free cash flow: -87897000 Unit1 Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -83731000 Unit1 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1730634 Filing: 000155837018002031 Input fundies:CapitalExpenditure: 4166000 Unit1 (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1852439 Filing: 000155837018002031 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−Unit1 125.2 million Exact value Exact value: -125200000 Unit1 2017-01-01 – 2017-12-31: -125200000 Unit1 Inspect Net Income Open source Share or cite Citation for Net Income · Aralez Pharmaceuticals Inc. · 2017-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Net Income: -125200000 Unit1 Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit1&dimensions= Input fundies:NetIncome: -125200000 Unit1 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018004351/arlz-20180331.xml#910880 Filing: 000155837018004351 The citation records this snapshot. The page link may show a newer release later.	−Unit1 28.8 million Exact value Exact value: -28800000 Unit1 2017-01-01 – 2017-12-31: -28800000 Unit1 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aralez Pharmaceuticals Inc. · 2017-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Operating Cash Flow: -28800000 Unit1 Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit1&dimensions= Input fundies:OperatingCashFlow: -28800000 Unit1 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018004351/arlz-20180331.xml#910365 Filing: 000155837018004351 The citation records this snapshot. The page link may show a newer release later.	Unit1 1.82 million Exact value Exact value: 1822000 Unit1 2017-01-01 – 2017-12-31: 1822000 Unit1 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aralez Pharmaceuticals Inc. · 2017-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Capital Expenditure: 1822000 Unit1 Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=Unit1&dimensions= Input fundies:CapitalExpenditure: 1822000 Unit1 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1852629 Filing: 000155837018002031 The citation records this snapshot. The page link may show a newer release later.	−Unit1 30.62 million Calculation and evidence -28800000 − 1822000 Unit1 Exact free cash flow: -30622000 Unit1 2017-01-01 – 2017-12-31: -28800000 Unit1 · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1822000 Unit1 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aralez Pharmaceuticals Inc. · 2017-12-31 Aralez Pharmaceuticals Inc. (edgar:1660719) Free cash flow: -30622000 Unit1 Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:43:31Z Snapshot: 22286fd7277300e08612be230d6cda5d7311919c2d8511640a5dff978494f5b3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1660719?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28800000 Unit1 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018004351/arlz-20180331.xml#910365 Filing: 000155837018004351 Input fundies:CapitalExpenditure: 1822000 Unit1 (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1660719/000155837018002031/arlz-20171231.xml#1852629 Filing: 000155837018002031 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

18 filings · 914 latest values · 914 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001660719, 1660719, edgar:1660719

Also known as Aralez Pharmaceuticals Inc., Old API Wind-down Ltd.

Aralez Pharmaceuticals Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation